Protein engineering to increase the potential of a therapeutic antibody Fab for long-acting delivery to the eye.

ABSTRACT: To date, ocular antibody therapies for the treatment of retinal diseases rely on injection of the drug into the vitreous chamber of the eye. Given the burden for patients undergoing this procedure, less frequent dosing through the use of long-acting delivery (LAD) technologies is highly desirable. These technologies usually require a highly concentrated formulation and the antibody must be stable against extended exposure to physiological conditions. Here we have increased the potential of a therapeutic antibody antigen-binding fragment (Fab) for LAD by using protein engineering to enhance the chemical and physical stability of the molecule. Structure-guided amino acid substitutions in a negatively charged complementarity determining region (CDR-L1) of an anti-factor D (AFD) Fab resulted i

SUBMITTER: Tesar D 

PROVIDER: S-EPMC5680807 | biostudies-literature | 2017 Nov/Dec

REPOSITORIES: biostudies-literature